US clears paediatric use of GSK’s Arnuity Ellipta
GlaxoSmithKline’s inhaled corticosteroid Arnuity Ellipta has been approved in the US for paediatric use.
US regulators have issued a green light for the once-daily inhaler as maintenance treatment of asthma in children from as young as five years.
The submission was supported by data from a pivotal study pitting the efficacy and safety of Arnuity Ellipta (fluticasone furoate) against placebo in 593 children aged 5 to 11 years (inclusive) with asthma.
Read more: http://www.pharmatimes.com/news/us_clears_paediatric_use_of_gsks_arnuity_ellipta_1236328
US regulators have issued a green light for the once-daily inhaler as maintenance treatment of asthma in children from as young as five years.
The submission was supported by data from a pivotal study pitting the efficacy and safety of Arnuity Ellipta (fluticasone furoate) against placebo in 593 children aged 5 to 11 years (inclusive) with asthma.
Read more: http://www.pharmatimes.com/news/us_clears_paediatric_use_of_gsks_arnuity_ellipta_1236328
